Skip to main content

Trinity College Dublin, The University of Dublin

Trinity Menu Trinity Search



You are here TRiCC Researchers

Professor Ed Lavelle
Prof/ Course Co-Ordinator, Biochemistry
Head of School, Sch Office - Biochemistry & Immunology

Biography

I am an Immunologist and have been Head of the School of Biochemistry and Immunology since 2017. I have engaged at teaching at many levels in Universities in Ireland and the U.K. In particular, since October 2004 I have worked as a lecturer, senior lecturer and Professor in Immunology in the School of Biochemistry and Immunology at Trinity College Dublin. In addition to delivering lectures and tutorials to junior and senior sophister students, I have also lectured to students enrolled on the MSc courses in Molecular Medicine, Immunology and Translational Oncology. I was also previously engaged in lecturing at TCD and at the University of Nottingham (England).

I have supervised student projects from diploma to Masters degree level and have supervised 17 PhD students to completion. I have been President of the Irish Society for Immunology since 2012, organised a number of National and International conferences, chaired sessions on Immunology and vaccines for a number of national and international conferences and acted as a peer reviewer for leading Immunology journals and for funding bodies in both the EU and the USA. Since acquiring my PhD in 1994, my research has been principally in the fields of Immunology and vaccine adjuvant development. The projects I have worked on have included the piscine mucosal immune system, the use of biodegradable micro and nanoparticles as vaccine adjuvants and the evaluation of plant lectins as bioadhesives, immunogens and immunomodulators. During this time I acquired broad expertise that is applicable to the range of projects I am now engaged in and will pursue in the future.

In recent years my principal research interest has been the elucidation of the mechanism of action of adjuvants and immunomodulators. In particular I have focused on on particulate vaccine adjuvants including biodegradable microparticles, alum and the cationic polysaccharide chitosan. This work includes basic research into the mechanism by which these systems activate the immune system and more applied work on the optimisation of these adjuvants for use in injectable and mucosal vaccines. The fundamental adjuvant research includes studies into the cell signalling pathways induced by these molecules which will facilitate a better understanding of their mode(s) of action. In addition, over the past number of years my team have worked closely with our collaborators within AMBER to address the potential of novel biomaterials to drive beneficial immune responses underpinning tissue regeneration. Across all of our activities we depend on building and sustaining close collaborations with national and international academic and industrial collaborators.

Publications and Further Research Outputs

Peer-Reviewed Publications

McEntee, C.P. and Finlay, C.M. and Lavelle, E.C., Divergent roles for the IL-1 family in gastrointestinal homeostasis and inflammation, Frontiers in Immunology, 10, (JUN), 2019 Journal Article, 2019 DOI TARA - Full Text

Lebre, F. and Lavelle, E.C. and Borges, O., Easy and effective method to generate endotoxin-free chitosan particles for immunotoxicology and immunopharmacology studies, Journal of Pharmacy and Pharmacology, 71, (6), 2019, p920-928 Journal Article, 2019 DOI

Nazmi, A., Field, R.H., Griffin, E.W., Haugh, O., Hennessy, E., Cox, D., Reis, R., Tortorelli, L., Murray, C.L., Lopez-Rodriguez, A.B., Lavelle, E.C., Dunne, A. and Cunningham,C. , Chronic neurodegeneration induces Type I interferon synthesis via STING, shaping microglial phenotype and accelerating disease progression, Glia, 67, 2019, p1254 - 1276 Journal Article, 2019 DOI TARA - Full Text

Carty, M. and Kearney, J. and Shanahan, K.A. and Hams, E. and Sugisawa, R. and Connolly, D. and Doran, C.G. and Muñoz-Wolf, N. and GÌrtler, C. and Fitzgerald, K.A. and Lavelle, E.C. and Fallon, P.G. and Bowie, A.G., Cell Survival and Cytokine Release after Inflammasome Activation Is Regulated by the Toll-IL-1R Protein SARM, Immunity, 50, (6), 2019, p1412-1424.e6 Journal Article, 2019 DOI

O'Grady, K., Hearnden, C.C.H., Bento, D., Oleszycka, E., Andersen, P., Muñoz-Wolf, N. and Lavelle, E.C. , IL-33 is a negative regulator of vaccine-induced antigen-specific cellular immunity, The Journal of Immunology, 2019 Journal Article, 2019

Sinéad Kenealy∗, Joan Manils∗, Mathilde Raverdeau Natalia Munoz-Wolf, Gillian Barber, Alex Liddicoat, Ed C.Lavelle Emma M.Creagh , Caspase-11 Mediated Cell Death Contributes to the Pathogenesis of Imiquimod-Induced Psoriasis, Journal of Investigative Dermatology, 2019 Journal Article, 2019 DOI TARA - Full Text

Jiménez, J.M. and Salazar, M.L. and Arancibia, S. and Villar, J. and Salazar, F. and Brown, G.D. and Lavelle, E.C. and Martínez-Pomares, L. and Ortiz-Quintero, J. and Lavandero, S. and Manubens, A. and Becker, M.I., TLR4, but neither dectin-1 nor dectin-2, participates in the mollusk hemocyanin-induced proinflammatory effects in antigen-presenting cells from mammals, Frontiers in Immunology, 10, (MAY), 2019 Journal Article, 2019 TARA - Full Text DOI

Liddicoat, A.M. and Lavelle, E.C., Modulation of innate immunity by cyclosporine A, Biochemical Pharmacology, 163, 2019, p472-480 Journal Article, 2019 DOI

Davitt, C.J.H. and Longet, S. and Albutti, A. and Aversa, V. and Nordqvist, S. and Hackett, B. and McEntee, C.P. and Rosa, M. and Coulter, I.S. and Lebens, M. and Tobias, J. and Holmgren, J. and Lavelle, E.C., Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines, Mucosal Immunology, 12, (4), 2019, p1055-1064 Journal Article, 2019 TARA - Full Text DOI

Lavelle, E.C. and McLachlan,J., Striking the right balance: using immunomodulators to target infectious diseases, cancer and autoimmunity, Current Opinion in Pharmacology, 41, 2018, pvii - ix Journal Article, 2018 DOI

Clancy, D.M. and Sullivan, G.P. and Moran, H.B.T. and Henry, C.M. and Reeves, E.P. and McElvaney, N.G. and Lavelle, E.C. and Martin, S.J., Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing, Cell Reports, 22, (11), 2018, p2809-2817 Journal Article, 2018 TARA - Full Text DOI

Oleszycka, E., McCluskey, S., Sharp, F.A., Muñoz-Wolf, N., Hams, E., Gorman, A.L., Fallon, P.G. and Lavelle EC., The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses., European Journal of Immunology, 2018, 705-715 Journal Article, 2018 DOI

Munoz-Wolf, N. and Lavelle, E.C., A Guide to IL-1 family cytokines in adjuvanticity, FEBS Journal, 285, (13), 2018, p2377 - 2401 Journal Article, 2018 DOI

Lebre, F., Pedroso de Lima, M.C., Lavelle, E.C. and Borges, O , Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles., International Journal of Pharmaceutics, 552, (112), 2018, p12 - 15 Journal Article, 2018 DOI

Moran, H.B.T., Turley, J., Andersen, M. and Lavelle, E.C , Immunomodulatory properties of chitosan polymers. , Biomaterials, 184, 2018, p1 - 9 Journal Article, 2018 DOI

Longet S, Lundahl MLE, Lavelle EC., Targeted Strategies for Mucosal Vaccination., Bioconjugate Chemistry, 29, (3), 2018, p613 - 623 Journal Article, 2018 DOI

Lebre, F., Hanlon, D., Boland, J.B., Coleman, J. and Lavelle E.C. , Exfoliation in Endotoxin‐Free Albumin Generates Pristine Graphene with Reduced Inflammatory Properties., Advanced Biosystems, 2, (12), 2018, p1800102- Journal Article, 2018

Lavelle, E.C. and McLachlan, J.B., Editorial overview: Immunomodulation: Striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity, Current Opinion in Pharmacology, 41, 2018, pvii-ix Journal Article, 2018 DOI

Lundahl, M.L.E. and Scanlan, E.M. and Lavelle, E.C., Therapeutic potential of carbohydrates as regulators of macrophage activation, Biochemical Pharmacology, 146, 2017, p23-41 Journal Article, 2017 DOI

Lebre, F., Sridharan, R., Sawkins, M.J., Kelly, D.J., O'Brien, F.J. and Lavelle, E.C., The shape and size of hydroxyapatite particles dictate inflammatory responses following implantation, Scientific Reports, 7, (1), 2017, p2922 - Journal Article, 2017 DOI TARA - Full Text

Harte, C., Gorman, A.L., McCluskey, S., Carty, M., Bowie, A.G., Scott, C.J., Meade, K.G. and Lavelle, E.C., Alum activates the bovine NLRP3 inflammasome, Frontiers in Immunology, 8, 2017, p1494- Journal Article, 2017 DOI

Munoz-Wolf, N. and Lavelle, E.C., Hippo interferes with antiviral defences, Nature Cell Biology, 19, (4), 2017, p267-269 Journal Article, 2017 DOI

Tivnan, A., Heilinger, T., Lavelle, E.C. and Prehn, J.H.M. , Advances in immunotherapy for the treatment of glioblastoma., Journal of Neuro-Oncology, 131, (1), 2017, p1-9 Journal Article, 2017 DOI TARA - Full Text

Moore C., Movia D., Smith R., Hanlon D., Lebre F., Lavelle E., Byrne H., Coleman J., Volkov Y., McIntyre J., Industrial grade 2D molybdenum disulphide (MoS2): an in vitro exploration of the impact on cellular uptake, cytotoxicity, and inflammation, 2D Materials, 4, (2), 2017 Journal Article, 2017 URL DOI

Longet, S., Aversa, V., O'Donnell, D., Tobias, J., Rosa, M., Holmgren, J., Coulter, I.S. and Lavelle, E.C., Thermostability of the coating, antigen and immunostimulator in an adjuvanted oral capsule vaccine formulation, International Journal of Pharmaceutics, 534, (1-2), 2017, p60-70 Journal Article, 2017 DOI

Barnes, D.D. and Lundahl, M.L.E. and Lavelle, E.C. and Scanlan, E.M., The Emergence of Phenolic Glycans as Virulence Factors in Mycobacterium tuberculosis, ACS Chemical Biology, 12, (8), 2017, p1969-1979 Journal Article, 2017 DOI

Hughes, C.S., Colhoun, L.M., Bains, B.K., Kilgour, J.D., Burden, R.E., Burrows, J.F., Lavelle, E.C., Gilmore, B.F., Scott, C.J., Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophages, Particle and Fibre Toxicology, 13, (1), 2016, p19- Journal Article, 2016 DOI TARA - Full Text

Ní Cheallaigh, C., Sheedy, F.J., Harris, J., Muñoz-Wolf, N., Lee, J., West, K., McDermott, E.P., Smyth, A., Gleeson, L.E., Coleman, M., Martinez, N., Hearnden, C.H., Tynan, G.A., Carroll, E.C., Jones, S.A., Corr, S.C., Bernard, N.J., Hughes, M.M., Corcoran, S.E., O'Sullivan, M., Fallon, C.M., Kornfeld, H., Golenbock, D., Gordon, S.V., O'Neill, L.A., Keane, J. Lavelle, E.C, A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling., Immunity, 44, (2), 2016, p368 - 379 Journal Article, 2016 URL TARA - Full Text

Innate immune receptors in, editor(s)Pablo Pelegrin and Francesco Di Virgilio , Nod Like Receptors, Springer, 2016, pp1-43 , [Muñoz-Wolf, N and Lavelle, E.C. ] Book Chapter, 2016

Lebre, F., Hearnden, C.H., Lavelle, E.C., Modulation of Immune Responses by Particulate Materials, Advanced Materials, 2016, 5525-5541 Journal Article, 2016 DOI

Finlay CM, Stefanska AM, Walsh KP, Kelly PJ, Boon L, Lavelle EC, Walsh PT, Mills KH., Helminth Products Protect against Autoimmunity via Innate Type 2 Cytokines IL-5 and IL-33, Which Promote Eosinophilia., Journal of Immunology, 196, (2), 2016, p703-714 Journal Article, 2016 DOI

Lavelle, E.C. and Tomar, J., Mucosal vaccines, adjuvants and delivery 2016 - A meetings management conference, Drugs of the Future, 41, (11), 2016, p689-695 Journal Article, 2016 DOI

Davitt, C.J.H., McNeela, E.A., Longet, S., Tobias, J., Aversa, V., McEntee, C.P., Rosa, M., Coulter, I.S., Holmgren, J., Lavelle, E.C., A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens, Journal of Controlled Release, 233, 2016, p162-173 Journal Article, 2016 DOI

Muñoz-Wolf N, Lavelle EC., Innate Immune Receptors., Methods Mol Biol., 1417, 2016, p1 - 43 Journal Article, 2016 DOI

Pandiyan P, Lavelle E.C, Editorial: Immune cells in the mucosa, Frontiers in Immunology, 7, (DEC), 2016, p00657- Journal Article, 2016 TARA - Full Text DOI URL

Carroll, E.C., Jin, L., Mori, A., Muñoz-Wolf, N., Oleszycka, E., Moran, H.B.T., Mansouri, S., McEntee, C.P., Lambe, E., Agger, E.M., Andersen, P., Cunningham, C., Hertzog, P., Fitzgerald, K.A., Bowie, A.G., Lavelle, E.C., The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons, Immunity, 44, (3), 2016, p597 - 608 Journal Article, 2016 DOI

Schwartz, C., O'Grady, K., Lavelle, E.C., Fallon, P.G., Interleukin 33: An innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer, European Journal of Immunology, 46, (5), 2016, p1091-1100 Journal Article, 2016 DOI

The Role of Inflammasomes in Adjuvant-Driven Humoral and Cellular Immune Responses in, editor(s)Virgil Schijns and Derek O'Hagan , Immunopotentiators in Modern Vaccines , 2016, pp23-42 , [Munoz-Wolf, N., McCluskey, S. and Lavelle, E.C.] Book Chapter, 2016 DOI

Oleszycka, E., Moran, H.B.T., Tynan, G.A., Hearnden, C.H., Coutts, G., Campbell, M., Allan, S.M., Scott, C.J. and Lavelle, E.C. , IL-1α and inflammasome-independent IL-1β promote neutrophil infiltration following alum vaccination. , FEBS Journal, 283, (1), 2016, p9 - 24 Journal Article, 2016 DOI

Kearney CJ, Cullen SP, Tynan GA, Henry CM, Clancy D, Lavelle EC, Martin SJ, Necroptosis suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine production., Cell death and differentiation, 22, 2015, p1313-1327 Journal Article, 2015 DOI

Brown AF, Murphy AG, Lalor SJ, Leech JM, O'Keeffe KM, Mac Aogáin M, O'Halloran DP, Lacey KA, Tavakol M, Hearnden CH, Fitzgerald-Hughes D, Humphreys H, Fennell JP, van Wamel WJ, Foster TJ, Geoghegan JA, Lavelle EC, Rogers TR, McLoughlin RM, Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection., PLoS pathogens, 11, (11), 2015, pe1005226 Journal Article, 2015 TARA - Full Text DOI

Davitt, C.J.H., Lavelle, E.C., Delivery strategies to enhance oral vaccination against enteric infections, Advanced Drug Delivery Reviews, 2015 Journal Article, 2015 DOI TARA - Full Text

Antigen Delivery Systems I: Nonliving Microparticles, Liposomes, and Immune-Stimulating Complexes (ISCOMs) in, Mucosal Immunology, 2015, pp1211-1231 , [McEntee, C., Lavelle, E.C., O'Hagan, D.T.] Book Chapter, 2015 DOI

Misstear, K., Mcneela, E.A., Murphy, A.G., (...), Mcloughlin, R.M., Lavelle, E.C. , Targeted nasal vaccination provides antibody-independent protection against staphylococcus aureus, Journal of Infectious Diseases, 209, (9), 2014, p1479-1484 Journal Article, 2014 TARA - Full Text DOI

Bourke J, Brereton CF, Gordon SV, Lavelle EC and Scanlan EM, The Synthesis and Biological Evaluation of Mycobacterial p-Hydroxybenzoic Acid Derivatives (p-HBADs), Organic & Biomolecular Chemistry, 12, (7), 2014, p1114-1123 Journal Article, 2014 TARA - Full Text

Misstear K, McNeela EA, Murphy AG, Geoghegan JA, O'Keeffe KM, Fox J, Chan K, Heuking S, Collin N, Foster TJ, McLoughlin RM, Lavelle EC, Targeted nasal vaccination provides antibody independent protection against Staphylococcus aureus., The Journal of infectious diseases, 209, (9), 2014, p1479-1484 Journal Article, 2014 DOI TARA - Full Text

Abautret-Daly AE, Davitt CJ, Lavelle EC, Harnessing the antibacterial and immunological properties of mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections., Biochemical pharmacology, 92, (2), 2014, p173-83 Journal Article, 2014 TARA - Full Text DOI

Tynan GA, Hearnden CH, Oleszycka E, Lyons CL, Coutts G, O'Connell J, Corrigan MA, Lynch L, Campbell M, Callanan JJ, Mok KH, Geoghegan J, O'Farrelly C, Allan SM, Roche HM, O'Shea DB, Lavelle EC, Endogenous oils derived from human adipocytes are potent adjuvants that promote IL-1 alpha-dependent inflammation., Diabetes, 63, (3), 2014, p2037-2050 Journal Article, 2014 TARA - Full Text DOI

Arancibia, S., Espinoza, C., Salazar, F., Del Campo, M., Tampe, R., Zhong, T-Y., De Ioannes, P., Moltedo, B., Ferreira, J., Lavelle, E.C., Manubens, A., De Ioannes, A.E. and Becker, M.I., A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata exhibits outstanding anti-tumor activity in melanoma., PLoS One, 9, (1), 2014, pe87240 Journal Article, 2014 DOI TARA - Full Text

Ismail M. Meraza, Claire H.A Hearnden, Xuewu Liua, Marie Yang, Laura Williams, Jianhua Gua, Jessica R. Rhudy, Kenji Yokoi, Ed C. Lavelle and Rita E. Serda , Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization increasing the anti-tumor efficacy of doxorubicin nanoliposomes, PLoS One, 2014, p0094703- Journal Article, 2014 DOI TARA - Full Text

Doyle SL, Ozaki E, Brennan K, Humphries MM, Mulfaul K, Keaney J, Kenna PF, Maminishkis A, Kiang AS, Saunders SP, Hams E, Lavelle EC, Gardiner C, Fallon PG, Adamson P, Humphries P, Campbell M, IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration., Science translational medicine, 6, (230), 2014, p230ra44 Journal Article, 2014 DOI TARA - Full Text

Doyle, SL, Ozaki, E, Brennan, K, Humphries, MM, Mulfaul, K, Keaney, J, Kenna, PF, Maminishkis, A, Kiang, AS, Saunders, SP, Hams, E, Lavelle, EC, Gardiner, C, Fallon, PG, Adamson, P, Humphries, P, Campbell, M, IL-18 Attenuates Experimental Choroidal Neovascularization as a Potential Therapy for Wet Age-Related Macular Degeneration, SCIENCE TRANSLATIONAL MEDICINE, 6, 2014, p230- Journal Article, 2014 DOI TARA - Full Text

Oleszycka, E. and Lavelle, E.C, The immunomodulatory properties of the vaccine adjuvant alum., Current Opinion in Immunology, 28C, 2014, p1 - 5 Journal Article, 2014 DOI

Tynan, GA, Hearnden, CH, Oleszycka, E, Lyons, CL, Coutts, G, O'Connell, J, Corrigan, MA, Lynch, L, Campbell, M, Callanan, JJ, Mok, KH, Geoghegan, J, O'Farrelly, C, Allan, SM, Roche, HM, O'Shea, DB, Lavelle, EC, Endogenous Oils Derived From Human Adipocytes Are Potent Adjuvants That Promote IL-1 alpha-Dependent Inflammation, Diabetes, 63, (6), 2014, p2037-2050 Journal Article, 2014 TARA - Full Text DOI

Arancibia, S., Espinoza, C., Salazar, F., Del Campo, M., Tampe, R., Zhong, T.-Y., De Ioannes, P., Moltedo, B., Ferreira, J., Lavelle, E.C., Manubens, A., De Ioannes, A.E., Becker, M.I., A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata promotes potent anti-tumor activity in melanoma, PLoS ONE, 9, (1), 2014, pe94703- Journal Article, 2014 DOI TARA - Full Text

Ruane, DT., Brane, L., Reis, B., Cheong, C., Poles, J., Do, Y., Zhu, H., Velinzon, K., Choi, J-H., Studt, N., Mayer, L., Lavelle, E.C., Steinman, R., Mucida, D and Mehandru, S. , Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract., The Journal of Experimental Medicine, 210, (9), 2013, p1871-1888 Journal Article, 2013 DOI TARA - Full Text

Adjuvant Strategies in Vaccines. in, editor(s)Prendergast/Jaffee , Cancer Immunotherapy: Immune Suppression and Tumor Growth, Academic Press, 2013, pp333-349 , [Hearnden, C and Lavelle, E.C.] Book Chapter, 2013

Cullen SP, Henry CM, Kearney CJ, Logue SE, Feoktistova M, Tynan GA, Lavelle EC, Leverkus M, Martin SJ, Fas/CD95-Induced Chemokines Can Serve as "Find-Me" Signals for Apoptotic Cells., Molecular cell, 49, 2013, p1-15 Journal Article, 2013 TARA - Full Text DOI

Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH, Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine., PLoS pathogens, 9, (4), 2013, pe1003264 Journal Article, 2013 TARA - Full Text DOI

Yang, M., Flavin, K., Kopf, I., Radics, G., Hearnden, C.H.A., McManus, G.J., Moran, B., Villalta-Cerdas, A., Echegoyen, L.A., Giordani, S. and Lavelle, E.C. , Chemical surface functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation, Small, 9, (24), 2013, p4194 - 4206 Journal Article, 2013

Kearney CJ, Sheridan C, Cullen SP, Tynan GA, Logue SE, Afonina IS, Vucic D, Lavelle EC, Martin SJ, Inhibitor of Apoptosis Proteins (IAPs) and Their Antagonists Regulate Spontaneous and Tumor Necrosis Factor (TNF)-induced Proinflammatory Cytokine and Chemokine Production., The Journal of biological chemistry, 288, (7), 2013, p4878-4890 Journal Article, 2013 DOI TARA - Full Text

Maher BM, Mulcahy ME, Murphy AG, Wilk M, O'Keeffe KM, Geoghegan JA, Lavelle EC, McLoughlin RM, Nlrp-3-driven interleukin 17 production by γδT cells controls infection outcomes during Staphylococcus aureus surgical site infection., Infection and immunity, 81, (12), 2013, p4478-4489 Journal Article, 2013 DOI

Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC, O'Neill LA, Hollyfield JG, Humphries P, NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components., Nature medicine, 18, (5), 2012, p791-798 Journal Article, 2012 DOI

McNeela, E.A. and Lavelle, E.C. , Recent advances in microparticles and nanoparticles for mucosal vaccination , Current Topics in Microbiology and Immunology, 354, 2012, p75-99 Journal Article, 2012 DOI

Cunningham CC, Mills E, Mielke LA, O'Farrell LK, Lavelle E, Mori A, McCarthy GM, Mills KH, Dunne A, Osteoarthritis-associated basic calcium phosphate crystals induce pro-inflammatory cytokines and damage-associated molecules via activation of Syk and PI3 kinase., Clinical immunology (Orlando, Fla.), 144, (3), 2012, p228-236 Journal Article, 2012 DOI

Immunostimulatory properties of biodegradable microparticles in, editor(s)John H. Morrow, Clint Schmidt, Nadeem Sheikh, Huw Davies , Vaccinology: Principles and Practice., Wiley-Blackwell, 2012, [Sharp, F.A. and Lavelle, E.C ] Book Chapter, 2012

Mori, A., Oleszycka, E., Sharp, F.A., Coleman, M., Ozasa, Y., Singh, M., O'Hagan, D.T., Tajber, L., Corrigan, O.I., McNeela, E.A., Lavelle, E.C., The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses, European Journal of Immunology, 42, (10), 2012, p2709-2719 Journal Article, 2012 DOI

Peral de Castro C, Jones SA, Ní Cheallaigh C, Hearnden CA, Williams L, Winter J, Lavelle EC, Mills KH, Harris J, Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion., Journal of immunology (Baltimore, Md. : 1950), 189, (8), 2012, p4144-4153 Journal Article, 2012 DOI

Campbell*, M, Doyle*, SL, Ozaki, E, Salomon, RG, Mori, A, Kenna, PF, Kiang, AS, Humphries, MM, Lavelle, EC, O'Neill, LAJ, Hollyfield, JG, and Humphries, P, NLRP3 plays a protective role during the development of age related macular degeneration through the induction of IL-18 by drusen components., Nature Medicine, 18, (5), 2012, p791 - 798 Journal Article, 2012 DOI

Schijns,V.E.J.C and Lavelle, E.C, Trends in vaccine adjuvants. , Expert Reviews in Vaccines., 10, (4), 2011, p539 - 550 Journal Article, 2011

Lavelle, E.C., McNaughton, A. and McNeela, E.A., NLRP3 in protective immunity and vaccination against respiratory infection, Expert Review of Vaccines, 10, (3), 2011, p255 - 257 Journal Article, 2011 DOI

Discovery of vaccine adjuvants in, editor(s)Editor Shane C. Gad. , Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing., John Wiley & Sons , 2011, pp1 - 14, [Sharp, F. and Lavelle, E.C.] Book Chapter, 2011

Afonina, I.S., Tynan, G.A., Logue, S. E., Cullen, S.P., Bots, M., Lüthi, A.U., Reeves, E.P., McElvaney, N.G., Medema, J.P., Lavelle, E.C. and Martin, S.J., Granzyme B-dependent proteolysis acts as a switch to enhance the pro-inflammatory activity of IL-1, Molecular Cell, 44, (2), 2011, p465 - 478 Journal Article, 2011 TARA - Full Text DOI

Future Trends of Novel Vaccine Adjuvants in, editor(s)Duc Hong Le, E , Immunologic Adjuvants, Future Science Group, 2011, pp104 - 116, [Schijns, V.E.J.C. and Lavelle, E.C] Book Chapter, 2011 DOI

Brereton, C.F., Sutton, C.E., Ross, P.J., Iwakura, Y., Pizza, M., Rappuoli, R., Lavelle, E.C., Mills, K.H.G., Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production, Journal of Immunology, 186, (10), 2011, p5896-5906 Journal Article, 2011 DOI

Ruane D.T and Lavelle E.C. , The role of CD103+ dendritic cells in the intestinal mucosal immune system. , Frontiers in Immunology , 2, 2011, p25 Journal Article, 2011 DOI

Rationales for including adjuvants in vaccines in, editor(s)Duc Hong Le , Novel Immunologic Adjuvants, Future Medicine Ltd, 2011, pp6 - 14, [Schijns, V.E.J.C. and Lavelle, E.C] Book Chapter, 2011 DOI

Harris, J..Hartman, M., Roche, C., Zeng, S.G., O'Shea, A., Sharp, F.A., Lambe, E.M., Creagh, E.M., Golenbock, D.T., Tschopp, J., Kornfeld, H., Fitzgerald, K.A. and Lavelle, E.C , Autophagy controls IL-1ß secretion by targeting pro-IL-1ß for degradation, The Journal of Biological Chemistry, 286, 2011, p9587 - 9597 Journal Article, 2011 TARA - Full Text

Ní Cheallaigh C, Keane J, Lavelle EC, Hope JC, Harris J., Autophagy in the immune response to tuberculosis: clinical perspectives., Clinical and Experimental Immunology, 164, (3), 2011, p291 - 300 Journal Article, 2011 DOI

Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH., Response: Characteristics of IL-17-Producing gammadelta T Cells., Immunity, 32, (1), 2010, p3 - 4 Journal Article, 2010 DOI

Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., Becker, C., Lavelle,E.C. and O'Neill, L.A.J., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β 2 in type 2 diabetes , Nature Immunology, 11, (10), 2010, p897-904 Journal Article, 2010 DOI

Harris, J., Sharp, F.A. and Lavelle, E.C, The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants , European Journal of Immunology , 40, (3), 2010, p634-638 Journal Article, 2010 DOI

Lavelle EC, Murphy C, O'Neill LA, Creagh EM, The role of TLRs, NLRs and RLRs in mucosal innate immunity and homeostasis , Mucosal Immunology, 3, (1), 2010, p17 - 28 Journal Article, 2010

McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, Moran B, Fitzgerald KA, Tschopp J, Pétrilli V, Andrew PW, Kadioglu A, Lavelle EC, Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4., PLoS pathogens, 6, (11), 2010, pe1001191 Journal Article, 2010 URL DOI TARA - Full Text

Thanavala,Y., Lavelle, EC. and Ogra,P. , All things mucosal, Expert Reviews in Vaccines , 8, (2), 2009, p139 - 142 Journal Article, 2009 DOI

Harris, J., Hope, J. and Lavelle, E.C. , Autophagy and the immune response to TB, Transboundary and Emerging Diseases , 56, (6-7), 2009, p248-254 Journal Article, 2009 DOI

Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH., Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease., Journal of Immunology, 183, (3), 2009, p1715-2173 Journal Article, 2009 DOI TARA - Full Text

Alexander U. Lüthi, Sean P. Cullen, Edel A. McNeela, Patrick J. Duriez, Inna S. Afonina, Clare Sheridan, Gabriela Brumatti, Rebecca C. Taylor, Kristof Kersse, Peter Vandenabeele, Ed C. Lavelle, and Seamus J. Martin, Suppression of Interleukin-33 Bioactivity through Proteolysis by Apoptotic Caspases, Immunity, 31, (1), 2009, p84-98 Journal Article, 2009 TARA - Full Text DOI

Oral delivery of vaccines in, editor(s)J Fix. and V H.L. Lee , Oral Peptide and Protein Drug Delivery, New York , Marcel Dekker, 2009, [Lavelle, E.C. and O'Hagan, D.T.] Book Chapter, 2009

Lavelle, E.C., Thanavala, J. and Ogra,P. , Mucosal immunity on the banks of the Duoro, Human Vaccines, 5, (5), 2009, p1 - 3 Journal Article, 2009 URL

Sutton, C.E., Lalor, S.J., Sweeney, C.M., Brereton, C.F., Lavelle, E.C. and Mills, K.H.G , Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity., Immunity, 31, (2), 2009, p331-341 Journal Article, 2009 TARA - Full Text DOI

Sharp, F., Ruane, D., Claas, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O'Hagan, D.T., Pétrilli, V., Tschopp, J., O'Neill, L.A.J. and *Lavelle, E.C, Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome., Proceedings of the National Academy of Sciences of the U.S.A, 106, (3), 2009, p870-875 Journal Article, 2009 DOI TARA - Full Text

Jarnicki, AJ, Conroy, H. Brereton, C, Donnelly, G., Toomey, D., Walsh, K.,, Sweeney, C., Leavy, O., Fletcher, J., Lavelle, E., Dunne, P. and Mills, K.H.G., Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics, Journal of Immunology, 180, (6), 2008, p3797 - 3806 Journal Article, 2008 TARA - Full Text URL

Sutton, C., Brereton, C., Keogh, B., Mills, K.H.G. Lavelle, E.C., A crucial role for IL-1 in the induction of IL-17 producing T cells that mediate autoimmune encephalomyelitis, The Journal of Experimental Medicine, 203, (7), 2006, p1685 - 1691 Journal Article, 2006

Lavelle E.C., Evaluation of the binding, uptake and immune responses elicited to orally administered lectins and microparticles, Methods , 38, (2), 2006, p84-89 Journal Article, 2006

Higgins, S., Jarnicki, A, Lavelle, E.C. and Mills, K.H.G, TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells, The Journal of Immunology, 177, 2006, p7980 - 7989 Journal Article, 2006 TARA - Full Text URL

Lavelle EC, Lectins and microparticles for enhanced oral vaccination, Methods, 38, (2), 2006, p84 - 89 Journal Article, 2006

Lavelle, E.C. and O'Hagan, D.T, Delivery systems and adjuvants for oral vaccines, Expert Opinion on Drug Delivery , 3, (6), 2006, p747 - 762 Journal Article, 2006 DOI

Lavelle, E.C., Grant, G., Pfuller,U. and O'Hagan, D.T, Type II ribosome-inactivating proteins from mistletoe are effective adjuvants when administered by mucosal and transcutaneous routes, Vaccine , Supplement 2, (S2), 2006 Journal Article, 2006

Mills, K.H.G., Higgins, S.H and Lavelle, E.C. , Tracheal Cytotoxin/ "Methods and compositions for modulating and immune response, 2006 Patent, 2006

Boyd, A.P., Ross, P.J., Conroy, H., Mahon, N Lavelle, E.C.and Mills, K.H.G., Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death, Journal of Immunology, 175, 2005, p730 - 738 Journal Article, 2005 URL TARA - Full Text

Lavelle, E.C, Generation of improved mucosal vaccines by induction of innate immunity., Cellular And Molecular Life Sciences, 62, (23), 2005, p2750-2770 Journal Article, 2005 DOI

Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KHG, Proinflammatory Responses in the Murine Brain after Intranasal Delivery of Cholera Toxin: Implications for the Use of AB Toxins as Adjuvants in Intranasal Vaccines, Journal of Infectious Diseases, 192, (9), 2005, p1628 - 1633 Journal Article, 2005 TARA - Full Text

Modified bacterial toxins in, editor(s)Charles J Hackett & Donald A Harn Jr, , Vaccine Adjuvants: Immunological and Clinical Principles., Publisher Humana, 2005, pp296 , [Lavelle EC., Leavy O. Mills KHG. ] Book Chapter, 2005

Lavelle, E., McGuirk and Mills, K.H.G., Molecules of infectious agents as immunomodulatory drugs, Current Topics in Med. Chem., 4, (5), 2004, p499 - 508 Journal Article, 2004 URL

Lavelle EC, Jarnicki A, McNeela E, Armstrong ME, Higgins SC, Leavy O, Mills KHG, Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent, Journal of Leukocyte Biology, 75, (5), 2004, p756 - 763 Journal Article, 2004 TARA - Full Text DOI

Ross, P.J., Lavelle, E.C., Mills, K.H.G. and A.P. Boyd., Adenylate cyclase toxin from Bordetella pertussis synergises with lipopolysaccharide to promote innate IL-10 production and enhance the induction of Th2 and regulatory T cells, Infection and Immunity, 72, (3), 2004, p1568 - 1579 Journal Article, 2004 TARA - Full Text DOI

Lavelle, E.C., McGuirk, P. and Mills, K.H.G. , Molecules of Infectious Agents as Immunomodulatory Drugs, Current Medicinal Chemistry , 4, (5), 2004, p499 - 508 Journal Article, 2004 URL

Lavelle EC., Grant G., Pfuller U. and O'Hagan D.T, Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract, The Journal of Drug Targeting , 12, (2), 2004, p89 - 95 Journal Article, 2004 DOI

Bowe, F., Lavelle, E.C., McNeela, E. A., Hale, C., Clare, S., Arico, B., Giuliani, M.M., Rae, A., Huett, A., Rappuoli, R., Dougan, G. and Mills, K. H.G., Mucosal vaccination against serogroup B meningococcus:Induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin, Infection and Immunity, 72, (7), 2004, p4052 - 4060 Journal Article, 2004 TARA - Full Text DOI

Mills, K.H.G., Boyd, A.P., Ross, P.J. and Lavelle, EC., , CyaA in the prophylaxis/treatment of inflammatory and immune-mediated disorders., 2003 Patent, 2003

Lavelle, E., McNeela, E., Armstrong, M., Leavy, O., Higgins, S.C. and Mills K.H.G., Cholera toxin promotes the induction of regulatory T cells by modulation dendritic cell activation, The Journal of Immunology, 171, 2003, p2384 - 2392 Journal Article, 2003 URL TARA - Full Text

Higgins, S., Lavelle, E., McCann, C., Keogh, B., McNeela, E, Byrne, P., O'Gorman, B., Jarnicki, A., McGuirk, P. and Mills, K.H.G., Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology, Journal of Immunology, 171, (6), 2003, p3119 - 3127 Journal Article, 2003 TARA - Full Text URL

Lavelle EC, Grant G, Pusztai A, Pfüller U, Leavy O, McNeela E, Mills KH, O'Hagan DT., Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2., Journal of Immunology, 107, (2), 2002, p268 - 274 Journal Article, 2002 DOI TARA - Full Text

O'Hagan, D.T and Lavelle, E. , Novel adjuvants and delivery systems for HIV vaccines, AIDS, 16, 2002, pS115 - S124 Journal Article, 2002

Lavelle, E.C, Targeted delivery of drugs to the gastrointestinal tract, CRC Critical Reviews in Therapeutic Drug Carrier Systems, 18, (4), 2001, p341 - 386 Journal Article, 2001

Lavelle, E.C., Grant, G., Pusztai,A., Pfüller,U and O'Hagan, D.T. , The identification of plant lectins with mucosal adjuvant activity, Immunology, 102, (1), 2001, p77 - 86 Journal Article, 2001 DOI

Lavelle, E.C., Chiron Corporation, Plant lectins as mucosal adjuvants. , 2001, WO0134193 Patent, 2001

Lavelle E.C, Patent update on drug delivery: January-June, Expert Opinion on Therapeutic Patents , 10, (9), 2000, p1335 - 1343 Journal Article, 2000

Lavelle, E.C., Grant, G., Pusztai,A., Pfüller,U and O'Hagan, D.T. , Mucosal immunogenicity of plant lectins in mice., Immunology, 99, (1), 2000, p30 - 37 Journal Article, 2000 DOI

Gill, I.J., Lin,W., Jenkins,P., Watts,P., Jiminez,M., Illum,L., Davis,S.S., Wood,J.M., Major,D., Minor,P.D., Li,X., Lavelle,E.C. and Coombes,A.G.A. , Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines, Vaccine, 18, (3-4), 2000, p238 - 250 Journal Article, 2000 DOI

Lavelle E.C, Targeted mucosal delivery of drugs and vaccines, Expert Opinion on Therapeutic Patents , 10, (2), 2000, p179 - 190 Journal Article, 2000 DOI

Delgado, A., Lavelle, E.C., Hartshorne,M. and Davis, S.S. , PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. , Vaccine, 12, (22), 1999, p2927 - 2938 Journal Article, 1999 DOI

Lectins in oral vaccination. in, editor(s)Eds, S. Bardocz., G. Hajós and A. Pusztai , COST 98-Effects of antinutrients on the nutritional value of legume diets., European Commission., 1999, pp148-159. , [Lavelle,E.C ] Book Chapter, 1999

Lavelle, E.C., Yeh, M.K., Coombes, A.G.A. and Davis, S.S., The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. , Vaccine, 17, (6), 1999, p512 - 529 Journal Article, 1999 DOI

Coombes, A.G.A., Lavelle,E.C. and Davis, S.S. , Biodegradable lamellar particles of poly (lactide) induce sustained immune responses to a single dose of adsorbed protein. , Vaccine, 17, (19), 1999, p2410 - 2422 Journal Article, 1999 DOI

Takahata, H., Lavelle, E.C., Coombes, A.G.A., Rafati, H. and Davis, S.S. , An investigation into the effects of exposure to digestive enzymes and polymer degradation on the integrity of microparticle-associated antigen. , The Journal of Controlled Release , 50, (1-3), 1998, p237 - 248 Journal Article, 1998

Coombes, A.G.A., Yeh, M-K., Lavelle, E.C. and Davis, S.S. , The control of protein release from poly (DL lactide-co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. , The Journal of Controlled Release, 52, (3), 1998, p311 - 320 Journal Article, 1998 DOI

Lavelle, E. C. and Harris, J. E. , The proteolysis of an orally administered protein antigen in the digestive tract of rainbow trout, Oncorhynchus mykiss (Walbaum,1792). , Comparative Biochemistry and Physiology, 117, (2), 1997, p263 - 275 Journal Article, 1997

Lavelle, E.C., Jenkins, P.G. and Harris, J.E. , Oral immunisation of rainbow trout with antigen microencapsulated in PLG microparticles. , Vaccine, 15, (10), 1997, p1070 - 1078 Journal Article, 1997 DOI

Coombes, A.G.A., Lavelle, E.C., Jenkins, P. G. and Davis, S. S. , Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen, Vaccine, 14, (14), 1996, p1429 - 1438 Journal Article, 1996 DOI

Thomas, N. W., Jenkins, P.G., Howard, K.A., Smith, M.W., Lavelle, E.C., Holland,J. and Davis, S.S. , Particle uptake and translocation across epithelial membranes, The Journal of Anatomy, 189, (3), 1996, p487 - 490 Journal Article, 1996 URL

Rafati, H., Lavelle, E.C., Coombes, A.G.A., Stolnik, S., Holland, J. and Davis, S.S., The immune response to a model antigen associated with PLG microparticles prepared using different surfactants, Vaccine, 15, (17-18), 1996, p1888 - 1897 Journal Article, 1996 DOI

Coombes, A.G.A., Lavelle, E.C., Jenkins, P. G., Holland, J. and Davis, S. S. , Biodegradable microparticles as parenteral vaccine delivery systems. , Developments in Biological Standardization , 87, 1996, p231- Journal Article, 1996

Lavelle, E.C., Sharif, S., Thomas, N. W., Holland, J. and Davis, S. S. , The importance of gastrointestinal uptake of particles in the design of oral delivery systems. , Advanced Drug Delivery Reviews, 18, (1), 1995, p5 - 22 Journal Article, 1995 DOI

Coombes, A.G.A., Lavelle, E.C., Jenkins, P.G. and Davis, S.S., Pulsed and sustained immune responses following a single dose of a model antigen associated with resorbable microparticles, Proceedings of International Symposium on the Controlled Release of Bioactive Materials. , 226-230, 1995, p560-561 Journal Article, 1995

Jenkins, P.G., Barton, R.N., Harris, J.E., Lavelle, E.C. and Wrathmell, A.B. , Enhanced delivery systems for enteric antigen uptake in teleosts, Vaccine, 10, 1992, p281-282 Journal Article, 1992

Research Expertise

Description

My research is principally focused on how vaccine adjuvants enhance and direct innate and adaptive immune responses. Adjuvants are essential components of vaccines that can profoundly affect the magnitude and type of adaptive immunity induced. My group concentrates on particulate adjuvants and over recent years has made key discoveries that enhance our understanding of how the physicochemical properties of particles influence the induction of innate and adaptive immunity. We have provided new insights into how particles engage innate cellular sensing pathways, particularly DNA sensing pathways and inflammasomes, pursuing the specific roles of interferons and cytokines of the IL-1 family in adjuvanticity. In addition, we have made advances in the development of novel injectable and mucosal vaccines, demonstrating that the optimal type of adjuvant depends the antigen and mode of vaccination. In particular, in collaboration with our industrial and academic colleagues we have worked on developing an effective oral delivery system that has significant potential for vaccines against ETEC, cholera and Helicobacter pylori. We are currently exploring avenues to progress this work towards clinical application. The expertise we have developed in assessing particulate regulation of immune responses has relevance in the field of biomaterial interaction with the immune system. As a result we now have a substantial research programme in this area as part of the AMBER centre. Being a CRANN PI and an AMBER funded investigator has led to my group beng closely connected to colleagues in Bioengineering, Chemistry and Physics and I see this cross-disciplinary dimension as a key driver of my research over the coming 5 years. I believe that this also underscores and supports the principal focus of the laboratory on dissecting how particulates can regulate immune responses and how fundamental understanding of the underlying processes can help us develop novel vaccine adjuvant systems but also enhanced biomaterials.

Projects

  • Title
    • Sugar coating immunity for enhancement of biomaterials.
  • Summary
    • 18/TIDA/6087.
  • Funding Agency
    • Science Foundation Ireland
  • Date From
    • 1-1-2019
  • Date To
    • 1-1-2020
  • Title
    • Irish Society for Immunology meeting 2018.
  • Summary
    • Proposal ID: 18/CW/5605.
  • Funding Agency
    • Science Foundation Ireland (SFI)
  • Date From
    • 1-6-2018
  • Date To
    • 31-12-2018
  • Title
    • European Congress of Immunology
  • Summary
    • The Business Tourism Unit of the National Tourism Development Authority (Fáilte Ireland) has approved an offer of grant assistance in respect of the above conference.
  • Funding Agency
    • Failte Ireland
  • Date From
    • 14-3-2018
  • Date To
    • 31-12-2024
  • Title
    • Investigating the role of Mal/TIRAP and the Mal- S180L SNP as determinants of susceptibility to pneumococcal disease and antipneumoco ccal vaccine efficacy
  • Funding Agency
    • European Society for Clinical Microbiolo gy and Infectious Diseases (ESCMID)
  • Date From
    • 1-5-2018
  • Date To
    • 31-10-2019
  • Title
    • SFI Research Centre, Advanced Materials and Bioengineering Research (AMBER) centre
  • Summary
    • Co-applicant for funding: Grant number SFI/12/RC/2278. Funded investigator. Projected budget to Ed Lavelle € 904,000k
  • Funding Agency
    • SFI
  • Date From
    • 2013
  • Date To
    • 2019
  • Title
    • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of cancer
  • Funding Agency
    • Trinity St. James's Cancer Institute
  • Date From
    • 2018
  • Date To
    • 2019
  • Title
    • Improving vaccine responses in the paediatric population by harnessing cytosolic nucleic acid sensing responses to promote Th1 and Th17 cell polarisation
  • Summary
    • Co-PI with Dr Sarah Doyle.
  • Funding Agency
    • National Childrens Research Centre
  • Date From
    • 1-1-2017
  • Date To
    • 31-12-2019
  • Title
    • Modulation of innate and adaptive immunity by particulate adjuvants for improved parenteral and mucosal vaccination.
  • Summary
    • 12/1A/1421.
  • Funding Agency
    • SFI
  • Date From
    • 2013
  • Date To
    • 2019
  • Title
    • Targeted oral delivery of cyclosporine to inhibit pathological intestinal IL-17 responses.
  • Summary
    • Project ID: EPSPG/2017/302.
  • Funding Agency
    • Irish Research Council
  • Date From
    • 1-1-2018
  • Date To
    • 1-1-2022
  • Title
    • RAdiosensitising Yb-1 Nano-antiBOdy (RAYNBO): a proof of concept study
  • Funding Agency
    • Trinity St. James's Cancer Institute
  • Date From
    • 2018
  • Date To
    • 2019
  • Title
    • Irish Society for Immunology meeting 2017
  • Funding Agency
    • Science Foundation Ireland (SFI)
  • Date From
    • 2017
  • Date To
    • 2017
  • Title
    • Investigating the Mal-IFN-γ axis as a determinant of morbidity and mortality in pneumococcal disease.
  • Summary
    • IRC award to Dr Natalia Munoz-Wolf.
  • Funding Agency
    • Irish Research Council
  • Date From
    • 1-10-2017
  • Date To
    • 31-9-2019
  • Title
    • Mechanism of action of chitin derived polymers
  • Funding Agency
    • Trinity College Dublin
  • Date From
    • 1-9-2017
  • Date To
    • 1-9-2021
  • Title
    • Mode of action of oral vaccine adjuvants
  • Summary
    • FNS P300PB_164740
  • Funding Agency
    • Swiss National Science Foundation (SNSF)
  • Date From
    • 1-2-2016
  • Date To
    • 31-1-2019
  • Title
    • Immunomodulatory properties of rhamnose
  • Summary
    • Trinity College Dublin College Award to Mimmi Lundahl. €39,000 (2015-2018)
  • Funding Agency
    • Trinity College Dublin
  • Date From
    • 1-10-2015
  • Date To
    • 1-10-2019
  • Title
    • Irish Society for Immunology meeting 2015.
  • Funding Agency
    • Science Foundation Ireland (SFI)
  • Date From
    • 1-6-2015
  • Date To
    • 31-12-2015
  • Title
    • Innate immune training: a memorable encounter with adjuvants
  • Summary
    • Project ID GOIPG/2015/4023. Aoife Gorman.
  • Funding Agency
    • Irish Research Council
  • Date From
    • 1-10-2015
  • Date To
    • 31-9-2019
  • Title
    • Irish Society for Immunology Workshop on the Microbiota and Clinical Immunology.
  • Summary
    • .14/CW/B016.
  • Funding Agency
    • Science Foundation Ireland (SFI)
  • Date From
    • 2014
  • Date To
    • 2014
  • Title
    • Targeting innate lymphoid cells in oral vaccination
  • Funding Agency
    • Saudi Arabian Government/Saudi Arabian Cultural Bureau.
  • Date From
    • 1-3-2015
  • Date To
    • 28-2-2019
  • Title
    • Advanced Immunization Technologies ADITEC
  • Summary
    • Co applicant: Affiliated member. Budget to Lavelle lab 47k.
  • Funding Agency
    • European Union
  • Date From
    • 2012
  • Date To
    • 2017
  • Title
    • HELICOVAXOR (2013), Development of novel mucosal vaccines against Helicobacter pylori infection.
  • Summary
    • Amount awarded is €1.3. Budget allocated to Dr Ed Lavelle €250,900. My role is as an RTD performer working on mucosal vaccination and determination of antigen specific cellular and humoral immunity.
  • Date From
    • 2013
  • Date To
    • 2015
  • Title
    • Targeted delivery of particulate vaccine adjuvants. (2011).
  • Summary
    • EPSPG/2012/404. Principal Investigator.
  • Funding Agency
    • Irish Research Council for Science, Engineering and Technology
  • Date From
    • 2010
  • Date To
    • 2013
  • Title
    • Targeted mucosal vaccines for HIV-Postgraduate award. 2010
  • Summary
    • Principal Investigator.
  • Funding Agency
    • Irish Research Council for Science, Engineering and Technology
  • Date From
    • 2010
  • Date To
    • 2013
  • Title
    • Development of novel immunostimulators to boost the immune system in cattle.
  • Summary
    • Adacemic Principal Investigator
  • Funding Agency
    • TEAGASC
  • Date From
    • 2012
  • Title
    • Immunomodulatory properties of nanoparticulates.
  • Summary
    • 12 month project focusing on carbon based nanoparticles. Time commitment 4%.
  • Date From
    • 2011
  • Title
    • European Mucosal Immunology Group meeting 2012
  • Summary
    • 12/CW/B2256. (EMIG2012).
  • Funding Agency
    • SFI
  • Date From
    • 2012
  • Title
    • Development of novel oral vaccines using LEDDS technology.
  • Summary
    • (2010).IRCSET-Sigmoid 2010-01. 2010-2013. Time commitment 4%.
  • Funding Agency
    • Irish Research Council for Science, Engineering and Technology
  • Date From
    • 2010
  • Date To
    • 2013
  • Title
    • Optimisation of liquid emulsion drug delivery system (LEDDS based oral vaccines to promote protective immunity against mucosal pathogens.
  • Summary
    • (2010). Proposal ID, IP20090046. Principal investigator.
  • Funding Agency
    • Enterprise Ireland
  • Date From
    • 2010
  • Date To
    • 2012
  • Title
    • Development of novel Liquid/Emulsion Drug Delivery System (LEDDS ) formulations for oral vaccination IP 2007 0451
  • Summary
    • Development of novel delivery systems for oral vaccination
  • Funding Agency
    • Enterprise Ireland
  • Date From
    • 2007
  • Date To
    • 2009
  • Title
    • Development of potent mucosal vaccines by combining an effective targeting agent with immunostimulatory particulate adjuvants.
  • Summary
    • Proposal ID, IP20090022. Principal investigator.
  • Funding Agency
    • Enterprise Ireland
  • Date From
    • 2010
  • Date To
    • 2012
  • Title
    • Can the ability of chitosan to promote innate immunity be harnessed to develop safe and potent adjuvants? (2008)
  • Summary
    • Proposal ID. 08/RFP/BMT1363. Principal Investigator.
  • Funding Agency
    • Science Foundation Ireland
  • Date From
    • 2008
  • Date To
    • 2011
  • Title
    • 'The Identification of novel immunomodulatory factors from Neisseria meningitidis serogroup B'
  • Summary
    • : Use of high throughput protein expression and dendritic cell screening technologies to identify novel adjuvants. Principal Investigator.
  • Funding Agency
    • Meningitis Research Foundation/Health Research Board
  • Date From
    • 2007
  • Date To
    • 2010
  • Title
    • SFI Strategic Research Cluster Grant. (2008).
  • Summary
    • Co-applicant for funding: Cluster. 7.5m. Co-applicant, PI Prof Kingston Mills. Budget allocated to Dr Ed Lavelle €794,498.
  • Funding Agency
    • SFI Strategic Research Cluster Grant.
  • Date From
    • 2008
  • Date To
    • 2012
  • Title
    • Mucosal vaccines for TB, HIV and malaria
  • Funding Agency
    • EU
  • Date From
    • 2004
  • Date To
    • 2009
  • Title
    • Development of novel Liquid/Emulsion Drug Delivery System (LEDDS ) formulations for oral vaccination (2007)
  • Summary
    • IP 2007 0451. Principal Investigator.
  • Funding Agency
    • Enterprise Ireland
  • Date From
    • 2007
  • Date To
    • 2009
  • Title
    • HRB PhD Scholars programme in Immunology.
  • Summary
    • Coapplicant for funding: Awarded to Trinity College Dublin in partnership with the Institute of Immunology (NUI Maynooth) and the Division of infection and Immunity (Queens University Belfast). Partner. Budget allocated to Dr Ed Lavelle (303,360).
  • Funding Agency
    • HRB
  • Date From
    • 2007
  • Date To
    • 2011
  • Title
    • Does Epac mediate a cyclic AMP-inducible pathway in dendritic cells that promotes pro-inflammatory T cell responses?
  • Summary
    • proposal ID: 07/RFP/BICF537. Principal Investigator.
  • Funding Agency
    • Science Foundation Ireland
  • Date From
    • 2007
  • Date To
    • 2010
  • Title
    • Determination of the potential of novel LEDDS formulations as oral vaccine delivery systems
  • Summary
    • IP 2006 0422 Principal Investigator
  • Funding Agency
    • Enterprise Ireland
  • Date From
    • March 07
  • Date To
    • May 07
  • Title
    • Mechanism of action of alum as a vaccine adjuvant.
  • Summary
    • Summary: Investigation of the mechanisms by which alum activates and polarizes T cell responses, focusing on its effects on dendritic cells. Principal Investigator.
  • Funding Agency
    • Irish Research Council for Science, Engineering and Technology
  • Date From
    • 2006
  • Date To
    • 2009
  • Title
    • Development of patented targeting technologies to produce oral vaccines.
  • Summary
    • IP 2006 0372. Summary: Investigation of novel cell targeting technologies to enhance mucosal vaccines. Principal Investigator.
  • Funding Agency
    • Enterprise Ireland
  • Date From
    • 2006
  • Date To
    • 2007
  • Title
    • A determination of the efficacy of LEDDS as an oral vaccine delivery system.
  • Summary
    • Summary: Investigation of novel delivery systems for oral vaccines. Principal Investigator.
  • Funding Agency
    • Sigmoid Biotechnologies Limited (2006).
  • Date From
    • 2006
  • Date To
    • 2007
  • Title
    • 'Mucosal vaccines for poverty related diseases'
  • Summary
    • Co-applicant for funding: Project acronym: MUVAPRED. Title of grant: . Amount awarded was €350,000. 2003-2007. Summary: Development of mucosal vaccines for malaria, TB and HIV using novel mucosal adjuvants and delivery systems. Partner.
  • Funding Agency
    • EU
  • Date From
    • 2003
  • Date To
    • 2007

Keywords

ADENYLYL-CYCLASE ACTIVITY; ADJUVANTS; cAMP; Cell Death; CREB; IL-10; Immune System; Immunity; Immunology, Immunotherapy; Immunophysiology; Inflammation; LECTIN-BINDING; LECTINS; Life Sciences; Nanotechnology; NF-kappaB; Signal Transduction; Signal Transduction (Sensory/Cellular); SIGNAL-TRANSDUCTION; SIGNAL-TRANSDUCTION PATHWAYS; Toll-Like Receptors; VACCINE; VACCINE EFFICACY; Vaccines

Recognition

Representations

Chair of the Steering committee for the Centre for Global Vaccine Research, University of Liverpool, U.K. (2017-2019).

Main organiser of 5 Immunology meetings including the Irish Society for Immunology meetings (2013-2018; average attendance 160-200 participants) and the European Mucosal Immunology Group (EMIG) 2012 meeting (300 participants), held in Dublin.

Member of the advisory board for the EU funded ITN, PHA-ST-TRAIN-VAC between the University of Strathclyde and GSK Vaccines (2017-2019).

National representative and member of the core group of the COST Action ENOVA (European Network of Vaccine adjuvants) 2018-2022.

Member of the Scientific Advisory Panel for 13 international conferences since 2006.

Won the bid to host the 2024 European Congress of Immunology in Dublin in 2024. I will lead the committee in planning for this meeting for the coming 5 years.

Member of the Editorial Board of Biochemical Pharmacology and Frontiers in Immunology

Awards and Honours

Fellow of Trinity College Dublin 2012

Made an ambassador of the Dublin Convention Centre 2018

Elected President of the Irish Society for Immunology 2013

Memberships

Irish Society for Immunology (President) 2005 (member) – 2019

European Adjuvant Advisory Group 2007 – 2008

European Federation of Immunology Societies 2005 – 2019

Society for Mucosal Immunology 2006 – 2019

The American Association of Immunologists 2018 – 2019